Humanoid robots perform live surgery: what happened and why it matters

What the trial involved

A team of engineers and surgeons at the University of California San Diego has reported the first demonstration of teleoperated humanoid robots performing live minimally invasive surgery on living animals. The work, published in Nature on 8 July 2026 under the title “In vivo feasibility study of humanoid robots in surgery”, moves general-purpose humanoid machines out of laboratory demonstrations and into the operating theatre — albeit in a preclinical setting (Times of India).

The platform, nicknamed “Surgie” by the researchers, is built around Unitree’s G1 humanoid robot rather than a purpose-built surgical system. The G1 stands roughly five feet tall, weighs about 60 pounds and uses standard laparoscopic instruments connected through custom adapters. Surgeons controlled the robots remotely via a console equipped with a stereo headset display and a foot pedal that engages or disengages hand-motion tracking (Ars Technica).

The preclinical trial involved two separate gallbladder removals on large non-primate mammals. In the first, a humanoid robot worked alongside a human surgeon who acted as assistant. In the second, two teleoperated humanoid robots worked in tandem, each handling laparoscopic instruments. Both procedures were completed successfully, according to the Times of India.

Why researchers built Surgie this way

Most robotic surgery platforms in use today — exemplified by Intuitive Surgical’s da Vinci system — are large, specialised machines. They are precise but expensive (often priced from around half a million dollars up to several million), can weigh roughly 1,800 pounds, and require specially configured operating rooms (Ars Technica). The UC San Diego team deliberately took the opposite route: instead of adapting a surgical robot to be more general, they adapted a general humanoid to perform surgery.

Unitree’s G1 is significantly cheaper. Ars Technica reports that a baseline G1 with effectively non-functional hands starts at around $13,500, and even an upgraded version with dexterous hands stays below roughly $67,000 — orders of magnitude below the da Vinci. The humanoid form factor also lets the robot move through spaces designed for people, which the researchers argue makes it easier to deploy in smaller hospitals, temporary facilities, emergency-response settings, or remote and rural clinics (Times of India).

Senior author Michael Yip, a professor in UC San Diego’s Department of Electrical and Computer Engineering, framed the longer-term ambition in humanitarian terms: “Remotely operated and autonomous humanoid robots have real potential for amplifying access to critical surgeries to which patients would otherwise not have access,” he said, adding that this could “help address the healthcare crisis not only in the United States, but also worldwide” (Times of India). Co-author Shanglei Liu, an assistant professor of surgery, similarly pointed to rural areas, the battlefield and even space as deployment environments (Ars Technica).

What the trial revealed about current limits

The successful procedures do not mean humanoid robots are ready for clinical use. The researchers flagged several technical bottlenecks. Because the G1 has an arm span of about 450 millimetres — versus 1.6 to 1.8 metres for an adult human — its reach is constrained, and the team had to pause the surgery for several minutes at a time to recalibrate the robots or reposition their bodies and arms relative to the instruments. As a result, the procedures took “much longer than when performed with existing specialized surgical systems” (Ars Technica).

Latency is another open issue. Current teleoperated humanoid platforms operate with latencies in the hundreds of milliseconds, while earlier research suggests surgical robots should ideally run below 150 milliseconds to be clinically safe. The UC San Diego team also reported that both new residents and experienced surgeons completed practice tasks faster using the da Vinci Research Kit — a standard telerobotic research platform — than when controlling the humanoid robots (Ars Technica). Together, these findings suggest the work demonstrates feasibility, not readiness.

Why it matters

The stakes of the trial are concrete. Healthcare systems in many countries face shortages of trained surgical staff while demand for treatment grows, producing delays and widening urban–rural disparities. If even teleoperated humanoid systems could be deployed at small hospitals without dedicated robotic surgery infrastructure, they could shift who has access to minimally invasive operations. The commercial angle matters too: da Vinci dominates the surgical-robot market today, and Ars Technica notes that humanoid platforms such as the G1 cost only a fraction of a da Vinci, suggesting potential pressure on incumbent pricing and on the standard model of purpose-built surgical robots.

There are also second-order consequences worth flagging. A teleoperated humanoid in a remote clinic would still depend on a trained surgeon somewhere else, so workforce distribution — not just equipment — would dictate real-world access. The use of a Chinese-made platform (Unitree) inside a US academic study, and the authors’ openness to eventual autonomous operation, also raise regulatory and geopolitical questions that go beyond the surgical lab.

Where the reporting diverges and what remains unconfirmed

The two sources broadly agree on the core facts: the team, the platform, the procedure (gallbladder removal on live pigs), and the publication outlet (Nature). They diverge mainly in emphasis. The Times of India piece foregrounds access-to-care framing and quotes Yip at length, presenting the trial as a milestone that could reshape operating rooms. Ars Technica is more cautious, foregrounding the technical gaps — latency, reach, calibration pauses, slower task completion — and reminding readers that da Vinci is FDA-cleared and clinically validated while the humanoid system remains experimental. Readers weighing the news should treat the Ars Technica account as the more technically sceptical baseline.

Several details remain unconfirmed or were not retrievable from the sources provided. The full text of one of the Times of India articles was truncated mid-quote from surgical resident Nikita Thareja, so her complete statement is not available here. Outcomes such as blood loss, complication rates, anaesthesia duration and post-operative recovery of the pigs are not specified in the excerpts, and whether the procedures were independently observed or peer-reviewed beyond Nature’s standard process is also not stated. The sources do not specify when, if ever, the team intends to begin human trials.

What to watch next

Three near-term signals will indicate whether this milestone translates into clinical progress. First, follow-up technical papers addressing the latency gap (currently hundreds of milliseconds versus a sub-150-millisecond target) and the G1’s reach constraints. Second, any movement toward regulatory engagement with bodies such as the US Food and Drug Administration, which has already cleared the da Vinci platform and would set the bar for any humanoid competitor. Third, commercial developments at Unitree and rivals — including price trajectories for dexterous-hand models, which today already push past $67,000 — since the access argument depends on humanoid robots remaining substantially cheaper than today’s surgical systems. Until at least two of these move, the trial should be read as a feasibility demonstration, not a clinical breakthrough.